Medindia

X

Sangui Bio Tech International Inc. Shareholders' Meeting Delayed to Include FY 2008 Report

Thursday, September 18, 2008 General News J E 4
Advertisement
WITTEN, Germany, September 17 Sangui BioTechInternational, Inc., is currently preparing its financial statements for its2008 financial year (ended June 30, 2008). The ensuing report on form 10KSBwill be filed with the SEC and made public in due course. It will be includedin the proxy materials for the forthcoming annual shareholders' meeting. Thiswas also requested in a letter by the SEC. Subsequently, the shareholders'meeting will be delayed by a few weeks. Shareholders will be informed aboutthe new schedule immediately after the pertaining resolutions will have beenpassed by the Board of directors.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTechInternational, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss futureexpectations, contain projections of results of operation or financialcondition or state other "forward-looking" information. These statements aresubject to known and unknown risks, uncertainties, and other factors thatcould cause the actual results to differ materially from those contemplatedby the statements. The forward-looking information is based on variousfactors and is derived using numerous assumptions. Important factors that maycause actual results to differ from projections include, among many others,the ability of the Company to raise sufficient capital to meet operatingrequirements. Words such as "anticipates," "expects," "intends," "plans,""believes," "seeks," "estimates," and variations of such words and similarexpressions are intended to identify such forward-looking statements. Unlessrequired by law, the Company undertakes no obligation to update publicly anyforward-looking statements, whether as a result of new information, futureevents or otherwise.For more information please contact: Joachim Fleing Phone: +49-(160)-741-27-17 Fax: +49-(2302)-915-191 e-mail: fleing@sangui.de

SOURCE Sangui Bio Tech International Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Good Indoor Air Quality in Schools is Vital for Pr...
S
CDC Director, Nation's Top Health Experts to Addre...